Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6981051rdf:typepubmed:Citationlld:pubmed
pubmed-article:6981051lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:6981051lifeskim:mentionsumls-concept:C0027819lld:lifeskim
pubmed-article:6981051lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:6981051lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:6981051lifeskim:mentionsumls-concept:C0332162lld:lifeskim
pubmed-article:6981051pubmed:issue4lld:pubmed
pubmed-article:6981051pubmed:dateCreated1982-10-21lld:pubmed
pubmed-article:6981051pubmed:abstractTextSeveral studies document the importance of immunity in the host-tumor relationship in neuroblastoma patients, evidentiating a correlation between clinical compromission and immune impairment. In this study we evaluated some aspects of cellular and humoral immune capacity in 50 neuroblastoma patients at onset. The aim of this investigation was to define, if any, the common immune pattern of these patients, and to evidentiate a possible correlation with prognosis. Immune tests performed were serum immunoglobulin quantitation, absolute value of total T and B lymphocytes, and lymphocyte reactivity to phytohemagglutinin (PHA), Concanavalin A (ConA), and Pokeweed mitogen (PWM). In patients with localized or regional disease, diminished values of lymphocytes were observed in 4/16 cases, a datum highly correlated to a poor final outcome (P less than 0.01). Mitogen response and serum immunoglobulin levels were frequently altered, but no prognostic value was evidentiated. Thirty-one children with disseminated disease presented more frequent and extended abnormalities: No parameter was found to correlate with prognosis, except for an impaired PHA response that paradoxically assumed a favourable prognostic meaning. Our results suggest that only the total lymphocyte number can contribute to predict the survival ratio in patients with regional disease.lld:pubmed
pubmed-article:6981051pubmed:languageenglld:pubmed
pubmed-article:6981051pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6981051pubmed:citationSubsetIMlld:pubmed
pubmed-article:6981051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6981051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6981051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6981051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6981051pubmed:statusMEDLINElld:pubmed
pubmed-article:6981051pubmed:issn0098-1532lld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:ToninoG JGJlld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:PasiniGGlld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:RosandaCClld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:De BernardiBBlld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:HauptRRlld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:BisogniM CMClld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:MaggioAAlld:pubmed
pubmed-article:6981051pubmed:authorpubmed-author:PonzoniMMlld:pubmed
pubmed-article:6981051pubmed:issnTypePrintlld:pubmed
pubmed-article:6981051pubmed:volume10lld:pubmed
pubmed-article:6981051pubmed:ownerNLMlld:pubmed
pubmed-article:6981051pubmed:authorsCompleteYlld:pubmed
pubmed-article:6981051pubmed:pagination321-30lld:pubmed
pubmed-article:6981051pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:meshHeadingpubmed-meshheading:6981051-...lld:pubmed
pubmed-article:6981051pubmed:year1982lld:pubmed
pubmed-article:6981051pubmed:articleTitleImmune evaluation of 50 children with neuroblastoma at onset.lld:pubmed
pubmed-article:6981051pubmed:publicationTypeJournal Articlelld:pubmed